Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.

Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T

Diabetes care1 May 2023Cited by 164 (Europe PMC)

PMID36857477PMCIDPMC10154650DOI10.2337/dc22-1710PepBankPUB-36857477

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg produced a greater fat mass reduction than placebo and semaglutide 1 mg.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg reduced fat mass more than placebo and semaglutide 1 mg.
Peptide
Tirzepatide
Outcome
DecreaseFat mass reduction
Study
n = 117
Comparator
Placebo and semaglutide 1 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747703
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg reduced body weight significantly more than placebo at week 28.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747701
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg reduced body weight significantly more than semaglutide 1 mg at week 28.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg led to more weight loss than semaglutide 1 mg.
Peptide
Tirzepatide
Outcome
DecreaseBody weight versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747702
04HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, tirzepatide 15 mg reduced appetite significantly more than placebo.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg reduced appetite more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseAppetite versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
15 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide and semaglutide significantly reduced appetite versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747704
05HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, appetite score reductions did not differ between tirzepatide 15 mg and semaglutide 1 mg.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg and semaglutide 1 mg reduced appetite scores by similar amounts.
Peptide
Tirzepatide
Outcome
No significant changeAppetite scores versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
15 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide
1 context sentence(design, population, supporting numbers)
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747705
06HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, energy intake reductions did not differ between tirzepatide 15 mg and semaglutide 1 mg.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg and semaglutide 1 mg reduced energy intake by similar amounts.
Peptide
Tirzepatide
Outcome
No significant changeEnergy intake versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 1 mg
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
15 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747706
07HumanRandomized controlled trialEfficacy outcome
In people with type 2 diabetes, semaglutide 1 mg significantly reduced appetite versus placebo at week 28.
In plain wordsIn people with type 2 diabetes, semaglutide 1 mg reduced appetite more than placebo.
Peptide
Semaglutide
Outcome
DecreaseAppetite versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide and semaglutide significantly reduced appetite versus placebo.
2 context sentences(design, population, supporting numbers)
Title · context
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747707
08HumanRandomized controlled trialEfficacy outcome
In people with type 2 diabetes, appetite score reductions with semaglutide 1 mg did not differ from tirzepatide 15 mg.
In plain wordsIn people with type 2 diabetes, semaglutide 1 mg and tirzepatide 15 mg reduced appetite scores to a similar extent.
Peptide
Semaglutide
Outcome
No significant changeAppetite scores versus tirzepatide
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide.
2 context sentences(design, population, supporting numbers)
Title · context
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747708
09HumanRandomized controlled trialEfficacy outcome
In people with type 2 diabetes, energy intake reductions with semaglutide 1 mg did not differ from tirzepatide 15 mg.
In plain wordsIn people with type 2 diabetes, semaglutide 1 mg and tirzepatide 15 mg reduced energy intake to a similar extent.
Peptide
Semaglutide
Outcome
No significant changeEnergy intake versus tirzepatide
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 mg · 28 weeksAs given in this study (human).
Source sentences
Summary
Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide.
2 context sentences(design, population, supporting numbers)
Title · context
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Summary · context
In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28.
Report a problemFND-3685747709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1Results postedNCT03951753

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Eli Lilly and Companyn = 11728 Jun 2019 to 8 Apr 2021

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 20 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC